Effect of Clarithromycin in Patients with Sepsis and Ventilator-Associated Pneumonia by Giamarellos-Bourboulis, Evangelos J. et al.
Clarithromycin for the Therapy of Sepsis • CID 2008:46 (15 April) • 1157
M A J O R A R T I C L E
Effect of Clarithromycin in Patients with Sepsis
and Ventilator-Associated Pneumonia
Evangelos J. Giamarellos-Bourboulis,1 Jean-Claude Peche`re,4 Christina Routsi,2 Diamantis Plachouras,1
Spyridon Kollias,2 Maria Raftogiannis,1 Dimitrios Zervakis,2 Fotini Baziaka,1 Apostolos Koronaios,2
Anastasia Antonopoulou,1 Vassiliki Markaki,2 Pantelis Koutoukas,1 Evangelos Papadomichelakis,3 Thomas Tsaganos,1
Apostolos Armaganidis,3 Vassilios Koussoulas,1 Anastasia Kotanidou,2 Charis Roussos,2 and Helen Giamarellou1
1Fourth Department of Internal Medicine, 2First Department of Critical Care Medicine, and 3Second Department of Critical Care Medicine,
University of Athens Medical School, Athens, Greece; and 4Department of Microbiology, University of Geneva Medical School, Geneva,
Switzerland
Background. Because clarithromycin provided beneficiary nonantibiotic effects in experimental studies, its
efficacy was tested in patients with sepsis and ventilator-associated pneumonia (VAP).
Methods. Two hundred patients with sepsis and VAP were enrolled in a double-blind, randomized, multicenter
trial from June 2004 until November 2005. Clarithromycin (1 g) was administered intravenously once daily for 3
consecutive days in 100 patients; another 100 patients were treated with placebo. Main outcomes were resolution
of VAP, duration of mechanical ventilation, and sepsis-related mortality within 28 days.
Results. The groups were well matched with regard to demographic characteristics, disease severity, pathogens,
and adequacy of the administered antimicrobials. Analysis comprising 141 patients who survived revealed that the
median time for resolution of VAP was 15.5 days and 10.0 days among placebo- and clarithromycin-treated
patients, respectively ( ); median times for weaning from mechanical ventilation were 22.5 days and 16.0Pp .011
days, respectively ( ). Analysis comprising all enrolled patients showed a more rapid decrease of the clinicalPp .049
pulmonary infection score and a delay for advent of multiple organ dysfunction in clarithromycin-treated patients,
compared with those of placebo-treated patients ( ). Among the 45 patients who died of sepsis, time toPp .047
death was significantly prolonged in clarithromycin-treated compared with placebo-treated patients ( ).Pp .004
Serious adverse events were observed in 0% and 3% of placebo- and clarithromycin-treated patients, respectively
( ).Pp .25
Conclusions. Clarithromycin accelerated the resolution of VAP and weaning from mechanical ventilation in
surviving patients and delayed death in those who died of sepsis. The mortality rate at day 28 was not altered.
Results are encouraging and render new perspectives on the management of sepsis and VAP.
Severe sepsis and septic shock develop among
11,500,000 patients each year in North America and
northern Europe, with a mortality rate range of 35%–
50% [1]. This considerable case fatality rate has focused
research attention on attempts to modulate the immune
response of the host. Several clinical trials have ex-
amined the application of antiendotoxin and anti–
TNF-a monoclonal antibodies and soluble receptors of
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TNF-a, but they failed to disclose considerable clinical
benefit [2].
Clarithromycin, a macrolide, is beneficial in some
pulmonary conditions, such as cystic fibrosis and dif-
fuse panbronchiolitis [3]. Its mechanism of action is
unclear, but, among other possible effects, anti-inflam-
matory properties have been suggested. In particular,
clarithromycin inhibits the biosynthesis of proinflam-
matory cytokines by human mononuclear cells in vitro
at concentrations of 2–10 mg/mL [4]. After intravenous
administration, clarithromycin prolonged survival in an
experimental model of acute pyelonephritis and sepsis
caused by both susceptible and multiresistant gram-
negative species. In these particular studies, clarithro-
mycin administration was associated with a deceased
secretion of proinflammatory mediators by blood
monocytes without affecting bacterial growth [5–9].
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Figure 1. Stages of the double-blind, randomized, placebo-controlled trial, with the number of patients at each stage. SAE, serious adverse event.
The present clinical trial was designed to test the efficacy of
clarithromycin in sepsis associated with ventilator-associated
pneumonia (VAP), a frequent and severe complication of me-
chanical ventilation in the intensive care unit (ICU) [10]. Se-
lecting a single cause of sepsis for this study eliminates the
possible bias introduced in some earlier studies, in which het-
erogeneous infections were combined for analysis [2].
PATIENTS AND METHODS
Study design. The study was a prospective, double-blind, ran-
domized, placebo-controlled, multicenter clinical trial that was
approved by the ethics committees of all hospitals of the par-
ticipating study sites and by the National Organization for Med-
icines of Greece (http://www.clinicaltrials.gov/; registration
number NCT00297674). During the period from June 2004
until November 2005, 218 patients were screened and 200 pa-
tients were enrolled (figure 1). After assigning 80% power to
achieve a 15% 2-sided difference between the 2 arms of treat-
ment regarding mortality and resolution of VAP, 100 patients
were assigned to receive placebo and 100 were assigned to re-
ceive clarithromycin. The mortality of the entire study popu-
lation was assessed during follow-up, and because no deviation
was observed from the expected rate, no interim analysis was
planned; the study was concluded when the last patient of 200
was enrolled. Patients were hospitalized at the Fourth Depart-
ment of Internal Medicine of “ATTIKON” University General
Hospital, the First Department of Critical Care of “Evangelis-
mos” General Hospital, and the Second Department of Critical
Care of “ATTIKON” University General Hospital (all in Athens,
Greece). The research microbiology laboratory of the Fourth
Department of Internal Medicine acted as the central laboratory
for the study.
Inclusion criteria were as follows: (1) written informed con-
sent provided by first- or second-degree relatives, (2) patient
intubation and mechanical ventilation for at least 48 h before
enrollment, (3) age 18 years, (4) diagnosis of VAP, and (4)
signs of sepsis. As a rule, written informed consent was asked
of the patients’ relatives on the third day after hospital
admission.
Exclusion criteria were as follows: (1) neutropenia, defined
as a neutrophil count !500 cells/mL; (2) HIV infection; (3) oral
intake of corticosteroids at a dose 1 mg/kg of equivalent
prednisone for a period 11 month; (4) administration of dro-
trecogin alfa in the previous 5 days; and (5) atrioventricular
block of second or third degree.
VAP was diagnosed in patients who presented with all of the
following: (1) new or persistent consolidation on lung radi-
ography, (2) purulent tracheobronchial secretions (TBSs), and
(3) a clinical pulmonary infection score (CPIS) 16 [11–15].
The CPIS was determined as assessed by Pugin et al. [16].
Sepsis was defined as the presence of at least 2 of the fol-
lowing [17]: (1) a core temperature 138C or !36C, (2) partial
pressure of carbon dioxide !32 mm Hg, (3) pulse rate 190/
min, and (4) WBC count 112,000 cells/mL or !4,000 cells/mL
Clarithromycin for the Therapy of Sepsis • CID 2008:46 (15 April) • 1159
Figure 2. Cumulative incidence of the resolution of ventilator-associ-
ated pneumonia within the follow-up period of 28 days. Analysis com-
prised patients who survived until the 28th day ( ). , bynp 141 Pp .036
Mantel-Cox log rank test; , by Tarone-Ware test; , byPp .017 Pp .011
the Breslow test.
Figure 3. Cumulative time to weaning from mechanical ventilation
among placebo-treated and clarithromycin-treated patients. Analysis com-
prised patients who survived until the 28th day ( ). , bynp 141 Pp .049
Mantel-Cox log rank test.
or 110% of band forms. Severe sepsis was defined as sepsis
accompanied by at least 1 organ failure, as described elsewhere
[17]. Septic shock was defined as sepsis accompanied by a
systolic blood pressure !90 mm Hg, necessitating the admin-
istration of vasopressors for 11 h [17].
Administration of treatment. Patients were randomly as-
signed to receive either placebo or clarithromycin treatment.
The allocated sequence was generated by an independent bio-
statistician. The study drug was prepared by an unblind in-
vestigator who had access to the randomization table; he did
not participate in any other stage of the study. Sealed envelopes
were used to implement the random allocation sequence. The
study drug was administered once daily within 1 h for 3 con-
secutive days by a nurse blind to treatment group. Each dose
of clarithromycin was 1 g. More precisely, 500 mg of white
amorphous powder contained in each of 2 vials (Abbott) was
dissolved in 20 mL of water for injection and was diluted to a
final volume of 250 mL of 5% glucose in water. Placebo con-
sisted of 20 mL of water for injection diluted to 250 mL of 5%
glucose in water. Administration was performed by an infusion
pump at a rate of 4.16 mL/min through a catheter connected
to a subclavian vein. The dosing of clarithromycin, 1 g/day,
was that recommended by the manufacturer. The total daily
dose was administered in a single infusion, not in 2 infusions
as usual, to provide higher serum concentrations. This ap-
proach was likely to provide at least 2 mg/mL in the serum
[18], a concentration shown to inhibit biosynthesis of IL-8 by
human monocytes [4] even in patients with septic shock and
increased volumes of distribution. All enrolled patients received
concomitant antimicrobials for the treatment of VAP as pre-
scribed by their attending physicians.
Evaluation of patients. Patients were observed for 28 days.
The following variables were recorded at baseline and follow-
up: (1) vital signs; (2) Acute Physiology and Chronic Health
Evaluation (APACHE) II score; (3) laboratory examination re-
sults; (4) blood gases and the ratio of partial pressure of oxygen
(PO2) to fraction of inspired oxygen (FiO2); (5) lung radio-
logical findings; (6) morphological appearance of TBSs; (7)
administered antimicrobial agents, vasopressors, hydrocorti-
sone, and insulin; and (8) positive blood culture results. For
each day of placebo or clarithromycin administration, all coad-
ministered medications were recorded, and a 12-lead electro-
cardiogram was performed with estimation of QTc. Daily visits
were performed at the same time of day as administration of
the first dose of the study drug.
Quantitative TBS cultures were performed at baseline and
on the fifth and tenth days of follow-up. Samples of TBSs were
collected after insertion of a sterile catheter into the intubation
tube or into the tracheotomy connected to a negative-pressure
device and were transported within 1 h to the central laboratory.
A total of 0.5 mL of TBS was added into a sterile tube with
0.5 mL of 1 mg/mL of dithiothreitol (Oxoid) and was diluted
5 consecutive times (1:10). Aliquots of 0.1 mL of each dilution
were plated onto MacConkey and blood agar (Becton Dick-
inson). Dishes were incubated for 5 days at 35C. Cultures that
yielded a pathogen at a count of  colony-forming61 10
units/mL were considered to be positive [19]. Identification of
pathogens was performed by the API20E and the API20NE
systems (bioMe´rieux). Susceptibility of the isolated pathogens
to antimicrobials was performed by the Kirby-Bauer disk dif-
fusion method with interpretation criteria according to the
Clinical and Laboratory Standards Institute [20].
A serious adverse event (SAE) was considered to be any
unexpected event that (1) led to death, (2) put the patient’s
life in danger, (3) prolonged hospitalization, (4) was accom-
panied by permanent or considerable disability, or (5) was ac-








Age, mean years  SD 58.40  17.41 58.41  20.74 .89
Age 65 years, no. (%) 50 (50) 55 (55) .48
Sex, M/F 73/27 74/26 1
APACHE II score, mean score  SD 17.32  6.23 16.88  5.99 .37
CPIS, mean score  SD
At baseline 7.92  1.94 7.62  0.93 .29
On day 5 6.10  2.43 5.23  2.51 .016
On day 10 5.88  2.32 5.09  2.48 .032
WBC count, mean cells/mL  SD 13,144.4  6701.1 11,390.4  4591.7 .20
PO 2:FiO2, mean  SD 218.5  110.3 224.8  103.2 .45
Reason for intubation, no. (%) .82
Respiratory failure due to chronic obstructive pulmonary disease 44 (44) 43 (43)
Multiple injuries 19 (19) 19 (19)
Cerebral ischemic attack or hemorrhage 21 (21) 26 (26)
Intra-abdominal infection 4 (4) 7 (7)
Celiac aortic aneurysm replacement 7 (7) 6 (6)
Other(s) 13 (13) 10 (10)
Predisposing factors, no. (%) .55
Diabetes mellitus type 2 14 (14) 16 (16)
Coronary heart disease 12 (12) 15 (15)
Hypertension 10 (10) 8 (8)
Cardiac failure 9 (9) 6 (6)
Other(s) 10 (11) 11 (11)
No. of patients with early/late VAP 44/56 41/59 .78
Time between ICU admission and VAP diagnosis, median days (IQR) 9.00 (3–48) 8.50 (3–54) .99
Administration of hydrocortisone, proportion (%) of patients 25/100 (25) 22/100 (22) .74
Administration of insulin, proportion (%) of patients 39/100 (39) 35/100 (35) .53
Critical illness, no. (%) of patients .95
Sepsis 26 (26) 25 (25)
Severe sepsis 31 (31) 33 (33)
Septic shock 43 (43) 42 (42)
106 CFU/mL in TBS, no. (%) 68 (68) 66 (66) .88
Type of pathogen, no. (%) of patients .28
Pseudomonas aeruginosa 12 (17.6) 17 (25.8)
Acinetobacter baumannii 43 (63.2) 36 (54.5)
Klebsiella pneumoniae 6 (8.8) 5 (7.6)
Enterobacter species 2 (2.9) 4 (6.1)
Stenotrophomonas maltophilia 2 (2.9) 0 (0)
Providentia stuartii 0 (0) 1 (1.5)
Other(s) 3 (4.4) 3 (4.5)
Incidence of bacteremia by the same isolate, no. (%) of patients 21 (21) 26 (26) .37
Type of administered antimicrobial agent, no. (%) of patients .11
Piperacillin-tazobactam 9 (9) 12 (12)
Carbapenem and vancomycin-linezolid 38 (38) 34 (34)
Carbapenem, colistin, and vancomycin-linezolid 27 (27) 31 (31)
Carbapenem monotherapy 8 (8) 4 (4)
Third-generation cephalosporins and clindamycin 16 (16) 16 (16)
Fluoroquinolones 2 (2) 1 (3)
Colistin 0 (0) 1 (1)
(continued)









Susceptibility of the TBS isolate to the administered antimicrobials,
proportion (%) of patients with isolate 42/67 (62.7) 49/65 (75.4) .44
Time between diagnosis of VAP and start of appropriate antimicrobial
therapy, median days (IQR) 0 (0–12) 0 (0–8) .93
Eradication of the pathogen on day 5, proportion (%) of patients with isolate 17/67 (25.4) 22/65 (33.8) .31
Eradication of the pathogen on day 10, proportion (%) of patients with isolate 21/67 (31.3) 19/65 (29.2) .82
NOTE. APACHE, Acute Physiology and Chronic Health Evaluation; CFU, colony-forming unit; CPIS, clinical pulmonary infection score; ICU, intensive
care unit; IQR, interquartile range; PO 2:FiO2, ratio of partial pressure of oxygen to fraction of inspired oxygen; TBS, tracheobronchial secretion.
companied by any grade IV laboratory abnormality. Organ fail-
ure and death related to sepsis were not assessed as SAEs.
Resolution of VAP encompassed all of the following, which
were assessed daily by the attending physicians: (1) absence of
purulent material in TBSs, (2) improvement of the infiltrate
on the lung radiography, (3) increase of the ratio of partial
pressure of oxygen to fraction of inspired oxygen, and (4) res-
olution of the signs of sepsis that led to study enrollment. Times
to resolution of VAP and deintubation were recorded. Case
reports were confirmed by a monitor blind to treatment group.
Statistical analysis. Unblinding for the study drug was per-
formed when follow-up of all patients was completed. Primary
end points were the number of days until resolution of VAP,
number of days receiving mechanical ventilation, and mortality
due to sepsis. The last was indirectly defined after exclusion of
all cases in which no clear relationship between death and the
underlying septic process could be found. All end points were
right censored on the 28th day.
Quantitative parameters were expressed by their mean
when they followed a normal distribution or by their me-SD
dian and interquartile range (IQR) for nonparametric param-
eters, as assessed by Kolmogorov-Smirnov statistics and com-
pared by Student’s t test or by Mann-Whitney U test,
respectively. Comparisons of qualitative characteristics were
performed by the x2 test.
The cumulative incidence of the resolution of VAP and of
weaning from the ventilator during the study period was de-
termined in patients who survived until the 28th day. The
cumulative time to death from sepsis was also determined for
patients who died. Comparisons were performed by the Man-
tel-Cox log-rank test, the Tarone-Ware test, and the Breslow
test. The impact of various factors on the cumulative incidence
of the resolution of VAP within the period of 28 days was
assessed by stepwise Cox regression analysis. These factors com-
prised type of therapy, sex, age 165 years, presence of septic
shock, and APACHE II score 115. Hazard ratios and 95% CIs
were estimated.
The most significant factor that affected survival was deter-
mined by Mantel-Haenszel statistical analysis. The effect of that
factor was separately evaluated for each group and was com-
pared with the Breslow-Day and Tarone tests. Any 2-sided P
value !.05 was considered to be statistically significant.
RESULTS
Study population. The first patient was enrolled on 23 June
2004, and the last was enrolled on 24 November 2005. Both
groups of patients were well matched for demographic char-
acteristics, underlying conditions, severity of sepsis, VAP-caus-
ing microorganisms, adequacy of and time to antibiotic treat-
ment, and eradication rates of causative bacteria (table 1). No
patient received a macrolide other than the study drug.
Effect of clarithromycin on resolution of VAP. On the 28th
day, 141 patients were alive. In the placebo group (72 survivors),
VAP resolved in 52 (72.2%) of cases within a median time of
15.5 days (25% and 75% interquartiles, 8.0 and 128.0 days,
respectively). In the clarithromycin group (69 survivors), VAP
resolved in 55 (79.7%) of the cases within a median time of
10.0 days (25% and 75% interquartiles, 5.0 and 18.0 days,
respectively). Curves of the cumulative percentages of the res-
olution of VAP during the follow-up reveal a significant dif-
ference between the 2 groups (figure 2). Cox regression analysis
of the cumulative incidence of the resolution of VAP revealed
that the only parameter that shifted the baseline function in a
significant manner was the administration of clarithromycin
(hazard ratio, 1.48; 95% CI, 1.00–2.20; ).Pp .048
When statistical analysis considered all enrolled patients, VAP
resolved in 54 of placebo-treated and in 61 of clarithromycin-
treated patients, with an earlier resolution in the latter group
(table 2). Among them, 38 and 39 patients, respectively, re-
ceived an adequate initial antimicrobial agent. Median (IQR)
times of resolution were 12 (2 to 128) days and 8 (2–24) days,
respectively ( , by comparison of the groups). In pa-Pp .017
tients whose VAP resolved, new infection and sepsis emerged
in 11 (20.4%) and 16 (26.3%) in the 2 groups, respectively
( ).Pp .37
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Crude mortality for any reason 28 31 .76
Mortality at 7 days 8 6 .78
Sepsis-related mortality at 28 days, no. of patients/total patients, excluding
those who died of other causes (%) 24/96 (25.0) 21/90 (23.3) .86
Progression to MODS among the total enrolled patients 8 14 .26
Time until progression to MODS, mean days  SD 3.38  1.06 5.78  3.52 .047
Time until resolution of VAP, median days (IQR) 11.5 (2 to 128) 7.0 (2–24) .006
Time in ICU after diagnosis of VAP for patients who survived, mean days  SD 21.58  8.22 23.36  7.05 .17
NOTE. Data are no. of patients, unless otherwise indicated. Clinical registry of the trial (NCT00297674) is available at http://www.clinical
trials.gov/. ICU, intensive care unit; IQR, interquartile range; MODS, multiple-organ dysfunction; VAP, ventilator-associated pneumonia.
Figure 4. Cumulative time to death from sepsis among placebo-treated
and clarithromycin-treated patients. Analysis comprised 24 placebo-
treated patients and 21 clarithromycin-treated patients who died, within
the follow-up period of 28 days, of sepsis due to ventilator-associated
pneumonia. , by Mantel-Cox log rank test; , by Tarone-Pp .004 Pp .030
Ware test; , by the Breslow test.Pp .011
Effect of clarithromycin on duration of mechanical
ventilation. Analysis comprised the 141 patients who sur-
vived until day 28. Weaning from mechanical ventilation oc-
curred in 42 (58.6%) of placebo-treated patients within a me-
dian period of 22.5 days (25% and 75% interquartiles, 12.0
and 128.0 days, respectively). Weaning from mechanical ven-
tilation occurred in 50 (72.5%) of clarithromycin-treated pa-
tients within a median period of 16.0 days (25% and 75%
interquartiles, 8.0 and 128.0 days, respectively). Curves of the
cumulative percentages of weaning from mechanical ventilation
over time showed that clarithromycin was beneficial (figure 3).
Effect of clarithromycin on mortality. Fourteen patients
died of a cause other than sepsis and were therefore excluded
from this analysis. Among the 186 remaining patients, 49 died
of sepsis: 24 (25.0%) of 96 patients in the placebo group and
21 (23.3%) of 90 patients in the clarithromycin group (Pp
, by comparison of the groups). Time to death was signif-.463
icantly prolonged among patients treated with clarithromycin
(figure 4).
The most significant factor associated with sepsis-related
death was the copresence of septic shock and multiple-organ
dysfunction (MODS), with a common OR of 7.70 (95% CI,
3.65–16.23; ). The OR was 19.00 (95% CI, 5.64–64.03)P ! .001
among placebo-treated patients and was 3.78 (95% CI, 1.36–
10.45) among clarithromycin-treated patients ( ).Pp .043
Adverse events. No study-drug–related SAE (0%) was ob-
served among patients receiving the placebo; 3 study-drug–
related SAEs (3%) were reported among patients treated with
clarithromycin ( ). These SAEs included 1 episode ofPp .25
bronchospasm 1 h after the end of administration of the study
drug on the second day. It occurred on an attempt at weaning
and was fully resolved; the patient discontinued treatment. Two
episodes of an increase in liver aminotransferase levels of 10
times the upper normal limit occurred. In the first patient,
elevation started 2 days before enrollment and became 10 times
the upper normal limit after the third dose of clarithromycin.
The elevation began to resolve within 3 days, in parallel with
discontinuation of coadministered meropenem. In the second
patient, elevation started on the second day after enrollment
and began to resolve after 2 days. Both patients remained part
of the study.
DISCUSSION
Intravenous administration of clarithromycin for 3 days was
associated with earlier resolution of VAP, more rapid decrease
of CPIS on days 5 and 10, earlier weaning from mechanical
ventilation in surviving patients, later death in those who died
of sepsis, and prolongation of the time of progression to MODS.
Although the ORs for death due to septic shock and MODS
were significantly decreased, globally, overall mortality among
study patients was not affected. Only 3 SAEs occurred.
These results may imply a dual action of clarithromycin in
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the study population. This action comprises (1) a shortening
of the physical course of VAP by 1.48 times, corresponding to
a median duration of 5.5 days (figure 2), which was accom-
panied by a median reduction of 6.5 days of the time me-
chanical ventilation was needed (figure 3), and (2) an effect on
the septic process itself, because the times to death from sepsis
and to progression to MODS were prolonged even if the overall
mortality due to sepsis was not affected (figure 4 and table 2).
The reduction of mechanical ventilation duration achieved with
clarithromycin treatment suggests an effect of the macrolide
drug on the respiratory function. In practical terms, we assume
that earlier weaning from the mechanical ventilation exposed
the patient to less risk of ventilator-associated infectious com-
plications. Earlier resolution of VAP by clarithromycin did not
increase the risk of new infections, in contrast with recent re-
sults that showed a positive correlation between methicillin-
resistant Staphylococcus aureus infection and former use of
azithromycin [21].
Although more-invasive techniques may provide better mi-
crobiological definitions, identification of the underlying path-
ogen was achieved in almost 70% of patients (134 patients).
The pathogens were gram-negative organisms in all cases, and
their eradication rate was similar in both groups (table 1). This
finding is in contrast to epidemiologic results from other coun-
tries, such as the United States, where gram-positive bacteria
predominate in VAP [22]. In Greece, multidrug-resistant gram-
negative species of Acinetobacter baumannii and Pseudomonas
aeruginosa are implicated in both early and late VAP; when S.
aureus emerges, it is resistant to methicillin and macrolides [23,
24]. The microbial causes of VAP in other European countries
also identified multidrug-resistant gram-negative species as the
main pathogens [10, 25].
The mechanism of action of clarithromycin in our patients
is difficult to assess, and only hypotheses can be raised. A con-
ventional antibiotic effect is unlikely, with consideration of the
gram-negative microbiology found in our patients. However,
a series of publications suggest a beneficial effect of macrolides
on the host in patients with chronic inflammatory disorders
of the airways and in animal models of infection. Diffuse pan-
bronchiolitis, cystic fibrosis, and bronchiectasis are chronic dis-
orders characterized by exacerbations of infections; patients are
often colonized with P. aeruginosa. Macrolides improve func-
tion of the lung by reducing infective exacerbations and inhibit
recruitment of neutrophils by reducing production of IL-8.
Moreover, they reduce sputum production and expectoration
[3, 26–28]. In vitro studies attributed their sputum production
and expectoration effect on their action on the tight junctions
between epithelial cells of the airways [29]. In the patients
colonized with P. aeruginosa, macrolides may also act as in-
hibitors of quorum sensing among bacteria that colonize the
airways [30]. Twenty-one infants with acute bronchiolitis
caused by the respiratory syncytial virus participated in a dou-
ble-blind, placebo-controlled trial [31]; 12 received oral clar-
ithromycin, 500 mg twice daily, for 3 weeks. Results showed a
clear decrease of the need for oxygen supplementation and of
the length of hospitalization in the clarithromycin arm com-
pared with results of the placebo-treated infants. An immu-
nomodulatory effect of clarithromycin seemed probable, since
serum concentrations of IL-4 and IL-8 were significantly de-
creased and the drug does not possess any antiviral activity.
Animal studies with acute pyelonephritis and sepsis by gram-
negative pathogens of Escherichia coli, Klebsiella pneumoniae,
and P. aeruginosa have shown that intravenous administration
of clarithromycin prolonged survival and reduced concentra-
tions of TNF-a in serum. The inflammatory reactions of tissues
were attenuated by clarithromycin without any change of tissue
bacterial load, whereas blood monocytes released lower
amounts of TNF-a [5–9]. These results favor the hypothesis
for an immunomodulatory effect of clarithromycin on the in-
flammatory cells of the host.
The presented results deserve consideration for at least 3
reasons. First, significant differences appeared despite the small
size of the population sample (100 patients per arm). Second,
enrolled patients were severely ill, with mean APACHE II scores
117 and mean CPISs 17. Accordingly, 59 patients (29.5%) died
during the 28-day period of observation, including 45 (22.5%)
deaths due to sepsis. Third, clarithromycin was administered
for only 3 days, a short period for the results obtained.
In conclusion, we consider our results to be encouraging.
However, to fully establish the actual potential of clarithro-
mycin in sepsis, other studies will have to be performed, with
larger populations and a prolonged clarithromycin regimen.
The relative good toleration seems to allow it.
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